BiotechTube
Cerium Pharmaceuticals

Cerium Pharmaceuticals

Cambridge, United States· Est.
ceriumpharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Cerium Pharmaceuticals is a private, clinical-stage biotech founded in 2020 and based in Cambridge, Massachusetts, targeting rare kidney diseases. Its lead program, a synthetic ACTH gel, has received FDA Orphan Drug Designation and is poised to enter Phase 3 trials for Primary Membranous Nephropathy (PMN), an area with no approved therapies. The company is led by a seasoned team with deep experience in rare disease drug development and commercialization, and is backed by a $12 million Series B financing round to advance its clinical plans.

NephrologyRare Diseases

Technology Platform

Repurposing and development of synthetic adrenocorticotropic hormone (ACTH) gel for rare kidney diseases.

Opportunities

The primary opportunity is to secure the first FDA approval for Primary Membranous Nephropathy (PMN), addressing a clear unmet need for ~75,000 US patients.
Orphan Drug Designation provides a pathway to 7 years of market exclusivity and regulatory benefits.
Successful development could position the company as an attractive acquisition target in the nephrology or rare disease space.

Risk Factors

The company faces high clinical risk as its entire value depends on the success of a single Phase 3 trial.
There is significant financing and execution risk, as the $12M Series B may be insufficient to complete Phase 3 development.
Competition from off-label therapies and potential new entrants also poses a market threat.

Competitive Landscape

There are currently no FDA-approved therapies for PMN, with treatment relying on off-label immunosuppressants like rituximab and cyclophosphamide. Cerium's synthetic ACTH aims to be a first-in-class, targeted therapy. However, the landscape is active with ongoing research into other mechanisms (e.g., B-cell and complement inhibition), which could yield future competitors.

More companies in United States →